AstraZeneca’s shares climbed nearly 2pc on Thursday morning, in a sign investors are expecting a renewed offer from US giant Pfizer. The rise follows three trading days of falls after AstraZeneca rebuffed Pfizer’s second cash-and-shares offer on Friday. Pfizer’s bid was worth around £63bn at the time, but the value has fallen to around £60bn due to a slide in Pfizer’s share price after it posted a 15pc fall in profits for the first quarter of the year.
Help employers find you! Check out all the jobs and post your resume.
